^
Association details:
| Biomarker: | TP53 mutation + MET amplification + PD-L1 overexpression |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
Published date:
11/06/2020
Excerpt:
Marginal zone lymphoma was diagnosed...The analysis of gene mutations showed that TP53 gene was mutated and MET gene was amplified….Given that PD-L1 were highly expressed on tumor cells, the MDT decided to treat the patient with sintilimab injection, a PD-1 inhibitor...after 10 treatments and 8 months of disease control, the patient’s condition was stable and the lung mass had shrunk further.
DOI:
10.3389/fimmu.2020.563622
